{"symbol":"AMGN","provider":"yahoo-finance","fetchedAt":"2025-12-24T01:49:18.213Z","asOfDate":"2025-12-23","articles":[{"id":"db37c64f-c540-3db5-ad9c-e926111259bd","title":"Halozyme Therapeutics Stock Sees Relative Strength Rating","url":"https://finance.yahoo.com/m/db37c64f-c540-3db5-ad9c-e926111259bd/halozyme-therapeutics-stock.html","publisher":"Investor's Business Daily","publishedAt":"2025-12-23T17:42:32.000Z","relatedTickers":["HALO"],"mainIdea":"Halozyme Therapeutics Stock Sees Relative Strength Rating","summary":"Investor's Business Daily: Halozyme Therapeutics Stock Sees Relative Strength Rating. Halozyme Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating Related tickers mentioned: HALO."},{"id":"835f1203-774b-3bde-9adb-960484c0e4bf","title":"Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?","url":"https://finance.yahoo.com/news/novo-nordisk-vs-amgen-healthcare-151400304.html","publisher":"Zacks","publishedAt":"2025-12-23T15:14:00.000Z","relatedTickers":["LLY","NONOF","NVO"],"mainIdea":"Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?","summary":"Zacks: Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?. NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison. Related tickers mentioned: LLY, NONOF, NVO."},{"id":"365f8e8a-12dd-3afc-b85f-9a89dded47c3","title":"5 Big Drug Stocks That May Continue to Outperform in 2026","url":"https://finance.yahoo.com/news/5-big-drug-stocks-may-134800671.html","publisher":"Zacks","publishedAt":"2025-12-23T13:48:00.000Z","relatedTickers":["ABBV","JNJ","LLY","^GSPC"],"mainIdea":"5 Big Drug Stocks That May Continue to Outperform in 2026","summary":"Zacks: 5 Big Drug Stocks That May Continue to Outperform in 2026. Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026. Related tickers mentioned: ABBV, JNJ, LLY, ^GSPC."},{"id":"69a3fc90-5c9a-3f39-ba20-b0a55ac4346e","title":"Dogs of the Dow Enhanced Income Strategy with Covered Calls","url":"https://finance.yahoo.com/m/69a3fc90-5c9a-3f39-ba20-b0a55ac4346e/dogs-of-the-dow-enhanced.html","publisher":"Barchart","publishedAt":"2025-12-23T12:00:02.000Z","relatedTickers":["^DJI"],"mainIdea":"Dogs of the Dow Enhanced Income Strategy with Covered Calls","summary":"Barchart: Dogs of the Dow Enhanced Income Strategy with Covered Calls. The Dogs of the Dow has long been a simple, rules-based approach to equity investing, built around owning the highest-yielding stocks in the Dow Jones Industrial Average. Each year, investors rotate into the 10 Dow components with the highest dividend yields, based on the assumption that these stocks are temporarily out of favor and may rebound over time. Related tickers mentioned: ^DJI."},{"id":"34a3a50e-f6af-3c87-bcd0-95f41ef39cc8","title":"Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know","url":"https://finance.yahoo.com/news/amgen-amgn-outpaces-stock-market-225001187.html","publisher":"Zacks","publishedAt":"2025-12-22T22:50:01.000Z","relatedTickers":["^DJI","^GSPC"],"mainIdea":"Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know","summary":"Zacks: Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know. The latest trading day saw Amgen (AMGN) settling at $331.39, representing a +1.22% change from its previous close. Related tickers mentioned: ^DJI, ^GSPC."},{"id":"65a995e2-731e-3bd8-ac46-a5c62b2ff7d7","title":"SCHD vs. NOBL: Different Paths to Dividend Stability","url":"https://finance.yahoo.com/m/65a995e2-731e-3bd8-ac46-a5c62b2ff7d7/schd-vs.-nobl%3A-different.html","publisher":"Motley Fool","publishedAt":"2025-12-22T21:31:52.000Z","relatedTickers":["SCHD"],"mainIdea":"SCHD vs. NOBL: Different Paths to Dividend Stability","summary":"Motley Fool: SCHD vs. NOBL: Different Paths to Dividend Stability. Both ETFs target dividend paying stocks, but their rules determine whether investors receive higher income or stricter dividend consistency Related tickers mentioned: SCHD."},{"id":"9ecc3ce3-9c26-3064-a686-e56ae6206c94","title":"Celldex Therapeutics Stock Gets RS Rating Lift","url":"https://finance.yahoo.com/m/9ecc3ce3-9c26-3064-a686-e56ae6206c94/celldex-therapeutics-stock.html","publisher":"Investor's Business Daily","publishedAt":"2025-12-22T20:42:10.000Z","relatedTickers":["CLDX"],"mainIdea":"Celldex Therapeutics Stock Gets RS Rating Lift","summary":"Investor's Business Daily: Celldex Therapeutics Stock Gets RS Rating Lift. A Relative Strength Rating upgrade for Celldex Therapeutics shows improving technical performance. Will it continue? Related tickers mentioned: CLDX."}]}
